Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1605999 | 1.00 | CTRB1 (0.58) | CTRB1HTTFOLH1SYKMME | |
| SCHEMBL5198016 | 1.00 | CTRB1 (0.58) | CTRB1HTTFOLH1SYKMME | |
| SCHEMBL116393 | 0.89 | CTRB1 (0.56) | CTRB1SYKATMCTSK | |
| SCHEMBL27577300 | 0.89 | CTRB1 (0.58) | CTRB1HTTFOLH1SYKMME | |
| SCHEMBL1570467 | 0.88 | CTRB1 (0.61) | CTRB1SYKATMCTSKTACR1 | |
| SCHEMBL15664942 | 0.88 | CTRB1 (0.61) | CTRB1SYKATMCTSKTACR1 | |
| SCHEMBL1570465 | 0.88 | CTRB1 (0.61) | CTRB1SYKATMCTSKTACR1 | |
| SCHEMBL4829896 | 0.88 | CTRB1 (0.68) | CTRB1SYKATMCTSKTACR1 | |
| SCHEMBL6428794 | 0.88 | CTRB1 (0.54) | CTRB1SYKCASP1ATMCTSK | |
| SCHEMBL6428792 | 0.88 | CTRB1 (0.54) | CTRB1SYKCASP1ATMCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574858-B | Bicyclic heterocycles and their use as CCR2 receptor antagonists | HOFFMANN LA ROCHE | 2015-06-24 | — | — | CN | disclosed |
| EP-2491022-B1 | DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| EP-2486042-B1 | BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8471004-B2 | Bicyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2013-06-25 | — | — | US | disclosed |
| EP-2486042-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| CN-102574858-A | Bicyclic heterocycles and their use as CCR2 receptor antagonists | HOFFMANN LA ROCHE | 2012-07-11 | — | — | CN | disclosed |
| WO-2011042399-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082294-A1 | NOVEL BICYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082294-A1 | NOVEL BICYCLIC COMPOUNDS | CCR2, CCR3, CCR1 | CTRB1 1520/4885HTT 4647/4885FOLH1 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.